| |
|
| Source: Company documents |
|
| Name
: |
Alexis Borisy |
| Title
: |
President, Chief Executive Officer, Director |
| Since: |
03/2000 |
|
|
|
| Name
: |
Robert Forrester |
| Title
: |
Chief Financial Officer, Executive Vice President |
| Since: |
02/2004 |
|
|
|
|
| Name
: |
Richard F. Pops |
| Title
: |
Director |
| Since: |
10/2001 |
|
|
|
| Name
: |
Jason F. Cole |
| Title
: |
Senior Vice President, General Counsel |
| Since: |
01/2006 |
|
|
|
| Name
: |
Lynn G. Baird |
| Title
: |
Senior Vice President, Regulatory, Quality, and Clinical Operations |
| Since: |
04/24/2006 |
|
|
|
| Name
: |
John Randle, Ph.D. |
| Title
: |
Senior Vice President, Commercial Development |
| Since: |
09/2007 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 6th August 2008 , 6th May 2008 , 6th March 2008 , 31st October 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| Technical Companies Soar in Debut Nov 13, 1:07 PM EST |
| ISE marked the best IPO debut, closing up 69% from its offer price |
| Aspreva's shares rose 34.5% on the first day of trading |
|
| More... |
|
| |
Combinatorx Inc.
All of the Company’s product programs are focused on diseases with continuing medical need and potentially large commercial markets. The Company’s three principal drug development programs are in immuno-inflammatory diseases, oncology and metabolic diseases. The Company’s largest development program is focused on the treatment of immuno-inflammatory diseases. The Company currently has six clinical stage drug development programs focused on immuno-inflammatory diseases.
|
| More... |
|
|
|
